FKBP12 Gene Editing in Human Tregs to Resist Tacrolimus

A 2026 study by Christopher J. Requejo Cier, shared on figshare, investigates the effect of FKBP12 knockout on human regulatory T cells (Tregs) under tacrolimus immunosuppression. The dataset is a 2.2 MB PDF containing results from a seven-day culture experiment with tacrolimus (10 ng/mL) and varying IL-2 concentrations (100–500 IU/mL). It demonstrates that FKBP12 deletion via CRISPR-Cas9 preserves Treg proliferation without altering phenotype or suppressive function.

Use Cases

• Analyzing the relationship between FKBP12 deletion and Treg proliferation under immunosuppression based on the described experimental conditions.
• Studying transcriptomic stability in gene-edited Tregs based on the mention of a global transcriptomic profile.
• Investigating the phenotypic markers of edited Tregs based on the described retention of FOXP3 expression.
• Evaluating a potential strategy to combine Treg therapy with calcineurin inhibitor treatment based on the study's proposed approach.

Strengths

• Dataset is associated with a specific, peer-reviewed scientific study described in detail.
• Experimental conditions are precisely defined, including tacrolimus concentration (10 ng/mL) and IL-2 range (100–500 IU/mL).
• Data is openly licensed under CC-BY-4.0 for reuse.

Limitations

• The primary data format is a PDF (2.2 MB); underlying raw or tabular data is not directly accessible.
• Row count and column-level documentation are unknown, which may limit suitability assessment.
• Data may reflect the specific experimental bias inherent to the described in vitro study.

Provenance

Source

Christopher J. Requejo Cier via figshare.

Collection Method

Data generated from an in vitro study using CRISPR-Cas9 gene editing and cell culture of human Tregs.

Time Range

Experimental data from a seven-day culture period.

Freshness

Last updated 2026-04-17 05:20:27.